Omega Therapeutics IPO Presentation Deck

In vivo PoC Data in Oncology Program - HCC Statistically significant reduction of tumor growth after 2 or 3 IV treatments every five days with OEC candidate in HCC xenograft tumor model (Hep3B) Tumor Volume (mm³) 1000- 800- 600- 400- 200- Negative Control OEC Candidate Small molecule comparator Ⓒ2021 Omega Therapeutics, Inc. 5 Day HHHH H*HH 10 % Body Weight Change from Baseline 20- 10- 10- -10- -20+ 10 I Negative Control OEC Candidate Small molecule comparator *Statistically significant vs negative control, t-test p<0.05 starting on day 6 Arrows denote dosing days 5 Day 10 20

View entire presentation